

Listing of Claims:

1. (Previously Presented). An anti-viral peptide-albumin conjugate comprising: an anti-viral peptide comprising a maleimide containing group and an amino acid sequence, wherein said sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits an anti-viral activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said peptide-albumin conjugate wherein the ratio of peptide to albumin in said conjugate is 1:1.

2. (Cancelled).

3. (Cancelled).

4. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 1.

5. (Cancelled).

6. (Previously Presented). An anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

7.-18. (Cancelled).

19. (Previously Presented). A composition for use in the treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an anti-viral peptide-albumin conjugate comprising an anti-viral peptide comprising a maleimide containing group and an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits an anti-viral activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to albumin in said conjugate is 1:1.

20. (Cancelled).

21. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:1.

22. – 30. (Cancelled).

31. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

32. – 35. (Cancelled).

36. (Previously Presented). A composition comprising the anti-viral peptide-albumin conjugate of claim 1 in a physiologically acceptable medium.

37. (Cancelled).

38. (Previously Presented). The composition of claim 36 wherein said amino acid sequence is SEQ ID NO:1.

39. (Previously Presented). The composition of claim 36 wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

40. – 58. (Cancelled).

59. (Previously presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said albumin is serum albumin.

60. (Previously presented). The anti-viral peptide-albumin conjugate of claim 59 wherein said albumin is human serum albumin.

61. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 3.

62. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 4.

63. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 5.

64. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 117.

65. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 118.

66. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 119.

67. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 534.

68. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 535.

69. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 536.

70. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 537.

71. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 538.

72. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 539.

73. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 540.

74. (Previously Presented). The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 541.

75. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:3.

76. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:4.

77. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:5.

78. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:117.

79. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:118.

80. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:119.

81. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:534.

82. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:535.

83. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:536.

84. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:537.

85 (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:538.

86 (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:539.

87. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:540.

88. (Previously Presented). The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:541.